Avrobio’s Gabriel Cohn Joins Homology as Chief Medical Officer

Homology Medicines (NASDAQ: [[ticker:FIXX]]) has appointed Gabriel Cohn to serve as its chief medical officer. Cohn was most recently vice president of clinical development at Avrobio (NASDAQ: [[ticker:AVRO]]). His experience also includes positions at Shire, Baystate Medical Center, and the Tufts University School of Medicine. Homology, which is developing gene-editing medicines and gene therapies, raised $144 million in its IPO last year. The Bedford, MA-based company is developing drugs based on a process called homologous recombination, which it says could offer advantages compared to other gene editing approaches, such as CRISPR.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.